Curanex Pharmaceuticals Inc (CURX)
CURX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CURX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0002025942 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
Recent IPO: no annual report filed yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $2.9M cash; operating cash flow -$3.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,568,216 (2026-11-13); 28,340,812 a year earlier. 1y figure adjusted for split (1-for-20 overall). | Cover page 2026-11-13 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2026-08-20 | Source 2026-08-20 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kreit & Chiu CPA LLP, Los Angeles, California, United States | PCAOB Form AP 2026-04-22 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2025-11-17 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$3.3M | -$1.1M | $2.9M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$3.2M | -$955K | $4.0M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$3.1M | -$857K | $5.0M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$954K | -$9.2M | $5.8M | No debt tags | Needs four quarters | 10-Q 2025-11-17 |
| Q2 2025 2025-06-30 | Not filed | -$60K | -$290K | $109K | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$138K | -$150K | Not filed | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$146K | -$95K | $149K | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | Not filed | -$91K | -$130K | Not filed | No debt tags | Needs four quarters | 10-Q 2025-11-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2025-08-26 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-10-19 |
Source: SEC EDGAR submissions feed, 66 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -22.7% |
| 1 month | -1.6% |
| 3 months | +9.6% |
| Year to date | -27.5% |
| 1 year | -56.6% |
| From 52-week high | -54.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMRN | Immuron Limited | $0.8996 | +2.23% | $7.3M |
| GTBP | GT Biopharma Inc. | $3.54 | -1.81% | $7.3M |
| LGVN | Longeveron Inc. | $2.14 | -14.06% | $7.2M |
| UPC | Universe Pharmaceuticals Inc. | $1.48 | -1.99% | $7.4M |
| XCUR | Exicure Inc. | $1.07 | -0.93% | $7.0M |
| MBRX | Moleculin Biotech Inc. | $7.14 | -9.28% | $7.6M |
| TPST | Tempest Therapeutics Inc. | $0.3418 | -10.50% | $6.8M |
| SNGX | Soligenix Inc. | $0.2882 | -10.22% | $6.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier